Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in London, GL, GB. The stock last traded at $35.80, down 0.91% on the session, giving a market capitalisation of $25.86B. On trailing twelve-month figures it carries a trailing P/E of -94.21, a net margin of -3534.9%. Its beta of 1.12 implies it has historically moved more than the broad market.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Roivant Sciences Ltd. is most often compared with the following Healthcare names: